{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:26:03Z","timestamp":1793805963366,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,19]],"date-time":"2027-08-19T00:00:00Z","timestamp":1818633600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:43:41Z","timestamp":1785271421000},"page":"298-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Germline testing in urothelial cancer: A narrative review of evidence, guidelines, and testing frameworks"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-8193","authenticated-orcid":false,"given":"Steven M.","family":"Monda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Else","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D.","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Humble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachery R.","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thenappan","family":"Chandrasekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mev","family":"Dominguez-Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Stoffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udit","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.07.004_bib0001","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0002","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.euo.2023.07.008","article-title":"Efficacy of National Comprehensive Cancer Network guidelines in identifying pathogenic germline variants among unselected patients with prostate cancer: the PROCLAIM trial","volume":"6","author":"Shore","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0003","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0004","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair\u2013deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0005","unstructured":"UroWeb EAU guidelines on upper urinary tract urothelial cell carcinoma: introduction. https:\/\/uroweb.org\/guidelines\/upper-urinary-tract-urothelial-cell-carcinoma accessed January 29, 2026."},{"key":"10.1016\/j.urolonc.2026.07.004_bib0006","unstructured":"American Urological Association Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline. https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/non-metastatic-upper-tract-urothelial-carcinoma accessed January 29, 2026."},{"key":"10.1016\/j.urolonc.2026.07.004_bib0007","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0008","unstructured":"UroWeb n.d. Non-muscle-invasive bladder cancer: introduction. https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer accessed March 24, 2026."},{"key":"10.1016\/j.urolonc.2026.07.004_bib0009","unstructured":"UroWeb n.d. EAU guidelines on MIBC \u2013 introduction. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer accessed March 24, 2026."},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.004_bib0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.004_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0012","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euros.2026.02.010","article-title":"Germline variants in bladder and upper tract urothelial cancers: prevalence and clinical context in a large testing registry","volume":"86","author":"Monda","year":"2026","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0013","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.19.01395","article-title":"Cancer susceptibility mutations in patients with urothelial malignancies","volume":"38","author":"Carlo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0014","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41436-019-0720-x","article-title":"Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma","volume":"22","author":"Nassar","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102451","article-title":"Pathogenic germline variant prevalence and genetic testing outcomes in patients with urothelial carcinoma","volume":"23","author":"Oh","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0016","article-title":"Inherited mutations in Chinese patients with upper tract urothelial carcinoma","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0017","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1158\/1078-0432.CCR-22-1006","article-title":"Inherited germline cancer susceptibility gene variants in individuals with non\u2013Muscle-invasive bladder cancer","volume":"28","author":"Pietzak","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0018","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bju.14370","article-title":"Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis","volume":"122","author":"Na","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000004089","article-title":"Germline pathogenic variants identified in patients with genitourinary malignancies undergoing universal testing: a multisite single-institution prospective study","author":"Choudry","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13053-023-00263-3","article-title":"Dominantly inherited micro-satellite instable cancer: the four Lynch syndromes: an EHTG, PLSD position statement","volume":"21","author":"M\u00f8ller","year":"2023","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101909","article-title":"Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database","volume":"58","author":"Dominguez-Valentin","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.humpath.2020.07.001","article-title":"Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome","volume":"103","author":"Chen","year":"2020","journal-title":"Human Pathol"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1147591","article-title":"Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors","volume":"13","author":"Rasmussen","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0024","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0025","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/cancers16030671","article-title":"Real-world data on institutional implementation of screening for mismatch repair deficiency and Lynch syndrome in endometrial cancer patients","volume":"16","author":"Joder","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41424-018-0047-y","article-title":"Barriers to Lynch syndrome testing and preoperative result availability in early onset colorectal cancer: a national physician survey study","volume":"9","author":"Noll","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0027","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0028","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.22.00205","article-title":"Durvalumab plus Olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: a multicenter, randomized, phase II trial (BAYOU)","volume":"41","author":"Rosenberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0029","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.22.00405","article-title":"A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma","volume":"41","author":"Crabb","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.urolonc.2026.07.004_bib0031","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0032","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair\u2013deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.004_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2025.04.005","article-title":"Clinical and genomic landscape of FGFR3 alterations across different stages of urothelial cancer","volume":"77","author":"Haas","year":"2025","journal-title":"Eur Urol Open Sci"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:27:51Z","timestamp":1793802471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005971"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline testing in urothelial cancer: A narrative review of evidence, guidelines, and testing frameworks","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}